Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acid phosphatase 4 (ACP4) is an integral membrane enzyme belonging to the histidine acid phosphatase family, with structural similarity to prostatic and lysosomal acid phosphatases[1][6]. It exhibits protein tyrosine phosphatase activity and binds receptor tyrosine kinases, notably ERBB4, where it may regulate their cleavage and signaling[2][4][7]. ACP4 is predominantly expressed in secretory-stage ameloblasts during tooth development, where it is essential for proper enamel formation—mutations in ACP4 cause hypoplastic amelogenesis imperfecta, characterized by thin and poorly mineralized enamel[1]. While its principal physiological role is in odontogenesis, ACP4's exact substrates, apart from possibly the ERBB4 receptor, remain insufficiently characterized in humans[2][7]. There are currently no known approved drugs selectively targeting ACP4, and its clinical significance is primarily in genetic and dental disorders rather than as a therapeutic target[1][2][6][7].
For inhibitors of acid phosphatase enzymes in general: Inhibition of phosphate monoester hydrolysis\n- No specific approved drugs targeting ACP4 are reported in the search results or primary literature
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acid phosphatase 4 (ACP4).